Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoke formula is a Traditional Chinese Medicine (TCM) herbal preparation investigated for the treatment of refractory type 2 diabetes mellitus, particularly in patients exhibiting the deficiency of Qi and Yin syndrome. The formula is designed to target Protein-tyrosine phosphatase 1B (PTP1B), a key negative regulator of the insulin signaling pathway. By inhibiting PTP1B, Xiaoke formula aims to enhance insulin sensitivity and improve glycemic control. It is typically evaluated as an adjunct to conventional therapies such as metformin and insulin. The development is led by Yueyang Hospital of Integrated Traditional Chinese and Western Medicine and the Shanghai University of Traditional Chinese Medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoke formula.